NCCN Collaborates with Bristol-Myers Squibb to Study PD-L1 Expression and Test Interpretation in Lung Cancer

NCCN is collaborating with Bristol-Myers Squibb to promote the advancement of scientific knowledge concerning programmed death-ligand 1 (PD-L1) protein expression and other immune markers in lung cancer. FORT WASHINGTON, PA - New molecules and pathways with pivotal functions in regulating the immune system have been discovered recently, providing new understanding of how tumor cells avoid the immune system. One of these molecules, named programmed cell death (PD-1), and molecules that interac...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news